Immunologic Change over 72 Weeks Following Raltegravir- Versus Efavirenz-Based Therapy in HIV/HCV-Coinfected Individuals in Vietnam.

Shikuma CM, Le T, Phuong TV, Chew GM, Nguyen VVC, Vo TL, Siriwardhana C, Chow D, Ghukasyan H, Limpruttidham N, Premeaux T, Gangcuangco LM, Paul R, Ndhlovu LC. Immunologic Change over 72 Weeks Following Raltegravir- Versus Efavirenz-Based Therapy in HIV/HCV-Coinfected Individuals in Vietnam. AIDS Res Hum Retroviruses. 2022 06; 38(6):441-450.

View in: PubMed

subject areas

Alkynes
Benzoxazines
Cyclopropanes
Hepacivirus
Hepatitis C
HIV Infections
HLA-DR Antigens
Humans
Neopterin
Vietnam

authors with profiles

Dominic Chow, MD, PhD, MPH
Cecilia M. Shikuma,MD
Lishomwa Ndhlovu, MD PhD
Chathura Siriwardhana, PhD

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support